Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | TroFuse-010: sacituzumab tirumotecan in HR+/HER2- metastatic breast cancer

Sara Tolaney • 17 Sep 2024
ESMO 2024
Breast Cancer Antibodies Sacituzumab tirumotecan
TroFuse-010

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, discusses the Phase III TroFuse-010 study (NCT06312176), exploring sacituzumab tirumotecan, an anti-TROP2 antibody-drug conjugate, in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC). The trial evaluates sacituzumab tirumotecan alone or in combination with pembrolizumab, compared to treatment of physician’s choice (TPC), and primary endpoints include progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sara Tolaney

Optimizing ADCs in mBC: boosting efficacy & managing toxicity in earlier treatment lines
1:11
Optimizing ADCs in mBC: boosting efficacy & managing toxicity in earlier treatment lines
Sara Tolaney • 20 Oct 2025
ADCs in earlier-line metastatic breast cancer: insights from DESTINY-Breast09 & ASCENT-03
2:02
ADCs in earlier-line metastatic breast cancer: insights from DESTINY-Breast09 & ASCENT-03
Sara Tolaney • 20 Oct 2025
Remaining questions surrounding the use of T-DXd in the curative-intent setting
2:02
Remaining questions surrounding the use of T-DXd in the curative-intent setting
Sara Tolaney • 20 Oct 2025
T-DXd vs T-DM1 in high-risk HER2+ breast cancer: DESTINY-Breast05 interim data
1:51
T-DXd vs T-DM1 in high-risk HER2+ breast cancer: DESTINY-Breast05 interim data
Sara Tolaney • 20 Oct 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals